Editorial Perspectives On Cell Line Development

1. From BPI West: An Upstream Scientist's Advice On Target Glycosylation 4/1/2025

   Bioprocess Online spoke to an upstream scientist at Bristol Myers Squibb during this year's BPI West. Here's what he had to say.

2. Using AI And ML To Gain Insight Into Optimal Glycoforms 3/28/2025

   Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.

3. GlycoNex On Challenges In Biosimilar Development, Manufacturing 1/29/2025

   In this written Q&A, GlycoNex president and CEO, Dr. Mei-Chun Yang, shares insight into the company's development of its denosumab biosimilar, SPD8. She covers the company’s approach to analytics, cell line development, scaling, and more.

4. ADCs: Leading With The Linker 12/20/2024

   Leo Marx, Ph.D., the Medicinal Chemistry Project and Bioconjugation Manager at Debiopharm, shares his company's rationale for the company's ADC development decisions and why its linker technology is the tip of the spear for those that make the cut.

5. Internalizing Nanoparticle Therapeutic Development 12/3/2024

   De facto approaches to treating immune-mediated diseases aren’t very kind to the immune system itself. COUR Pharmaceuticals is leveraging nanoparticles, a purpose-built platform and in-house expression systems to build antigen-specific therapies that treat the root cause of autoimmune diseases.

6. Discovery vs. Hypothesis-Driven Cell Line Development 10/8/2024

   Susan Sharfstein, Ph.D., explains how discovery-driven research can further our understanding of cellular biology and ultimately inform cell line development.

7. Complex Protein Development: Assay Early, Assay Often 9/6/2024

   Experts from FyoniBio, SOTIO, and Vera Therapeutics weigh in with first-hand experience on how process decisions made very early on can influence – beneficially or detrimentally – the efficiency of upstream and even downstream operations in the development of novel protein therapeutics.

8. Manufacturing CAR-T In Vivo 7/25/2024

   Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.

9. The Path To Producing An Insulin Biosimilar 7/17/2024

   I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.

10. Targeting The Gut–Brain Axis With Live Biotherapeutic Products 9/8/2023

    Treating seizures with bacteria — Bloom Science's CEO, Dr. Christopher Reyes, explains how his company aims to leverage the gut–brain axis using live biotherapeutic products (LBP).